Our network pharmacology study indicated that FGF-2 was one of the top 10 genes that WCAF can regulate in clone cancer, the validation assay showed that the expression of FGF-2 were statistically significantly lower in the WCAF group and combination treatment group in comparison to the control group and BEV monotherapy group. Here, FGF2 is linked to cancer.